Spelman, TimHerring, W. L.Acosta, C.Hyde, R.Jokubaitis, VilijaPucci, EugenioLugaresi, AlessandraLaureys, GuyHavrdova, EvaHorakova, DanaIzquierdo, GuillermoEichau, SaraOzakbas, SerkanAlroughani, RaedKalincik, TomasDuquette, PierreGirard, MarcPetersen, ThorPatti, FrancescoCsépány, TündeGranella, FrancoGrand'Maison, FrancoisFerraro, D.Karabudak, RanaJosé Sá, MariaTrojano, MariaPesch, Vincent vanVan Wijmeersch, BartCartechini, ElisabettaMcCombe, PamelaGerlach, OliverSpitaleri, DanieleRózsa, CsillaHodgkinson, SuzanneBergamaschi, RobertoGouider, RiadhSoysal, AysunPrevost, JulieGarber, Justinde Gans, KoenAmpapa, RadekSimó, MagdolnaSanchez-Menoyo, JoseIuliano, GerardoSas, AttilaWalt, Anneke van derJohn, N.Gray, OrlaHughes, StellaDe Luca, GiacomoOnofrj, MarcoBuzzard, KatherineSkibina, OlgaTerzi, MuratSlee, MarkSolaro, ClaudioRamo-Tello, CristinaFragoso, YaraShaygannejad, VahidMoore, FraserRajda, CecíliaAguera-Morales, EduardoButzkueven, Helmut2024-03-062024-03-062024Journal of Medical Economics. -27 : 1 (2024), p. 109-125. -J Med Econ. - 1369-6998. - 1941-837X1941-837X1369-6998https://hdl.handle.net/2437/367198Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdomfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM119143OrvostudományokElméleti orvostudományokhttps://www.tandfonline.com/doi/full/10.1080/13696998.2023.2293379szerzőhttp://dx.doi.org/10.1080/13696998.2023.22933792024-03-0600113039790000185181176590